23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...

Holding released a new polygenic risk score report on the genetics of osteoporosis for 23andMe+ Premium members. The report ...

A pioneer in genetic heritage services, 23andMe has seen much of its share price wiped out in the past year as it struggles ...

The testing company ended last year with $79 million and told investors it will need to raise money to fund its operations ...

Me (ME) forms special board committee to explore strategic alternatives, including sale, restructuring, or business ...

By the 2023 fiscal year, 23andMe had reported a net loss of $312 million and its individual share price has plummeted a ...

23andMe Holding Co. ( ME, Financials) announced that its board's Special Committee is reviewing strategic alternatives, ...

Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial ...

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year.

The Special Committee of the Board of Directors of 23andMe Holding Co. (Nasdaq: ME) ("23andMe" or the "Company"), a leading human genetics company ...

Manhattan Associates' 2025 outlook missed estimates. The provider of supply-chain and omnichannel-commerce solutions said it expects adjusted per-share earnings of $4.45 to $4.55 on revenue of $1.06 ...

Here's the latest M&A news and auction block updates. Among the most watched items: a TikTok deal is still in flux.